<DOC>
	<DOCNO>NCT01108978</DOCNO>
	<brief_summary>The purpose study evaluate Efficacy Safety Dehypotin® Patients Type 2 Diabetes Mellitus Cardiovascular Disease . Eligible patient randomly assign 1 2 arm , either Dehypotin® placebo , receive diet advisement throughout study .</brief_summary>
	<brief_title>Evaluating Efficacy Safety Dehypotin® Patients With Type 2 Diabetes Mellitus Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Male female Age 2075 year Diagnosis type II Diabetes Mellitus least 3 month and/or clinical evident cardiovascular disease ( CVD ) A hemoglobin A1c concentration &lt; 8 % screen Women child bear potential pregnant , breastfeed use effective contraceptive Known hypersensitivity Pravastatin component Have history homozygous familial hypercholesterolemia know type III hyperlipoproteinemia Significant medical illness Known serious condition , e.g . serum creatine kinase ( CK ) level 2.5 time upper limit normal Subjects treat drug influence serum lipid concentration Subjects cancer receive cancer chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>hypercholesterolemia</keyword>
</DOC>